{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:06:21Z","timestamp":1784203581357,"version":"3.55.0"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>Paroxysmal nocturnal hemoglobinuria (PNH) is a clonal disease of hematopoietic cells with a variable clinical spectrum characterized by intravascular hemolysis, high risk of thrombosis, and cytopenias. To understand the biochemical shifts underlying PNH, this study aimed to search for the dysfunctional pathways involved in PNH physiopathology by comparing the systemic metabolic profiles of affected patients to healthy controls and the metabolomic profiles before and after the administration of eculizumab in PNH patients undergoing treatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Plasma metabolic profiles, comprising 186 specific annotated metabolites, were quantified using targeted quantitative electrospray ionization tandem mass spectrometry in 23 PNH patients and 166 population-based controls. In addition, samples from 12 PNH patients on regular eculizumab maintenance therapy collected before and 24 hours after eculizumab infusion were also analyzed.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>In the PNH group, levels of the long-chain acylcarnitines metabolites were significantly higher as compared to the controls, while levels of histidine, taurine, glutamate, glutamine, aspartate and phosphatidylcholines were significantly lower in the PNH group. These differences suggest altered acylcarnitine balance, reduction in the amino acids participating in the glycogenesis pathway and impaired glutaminolysis. In 12 PNH patients who were receiving regular eculizumab therapy, the concentrations of acylcarnitine C6:1, the C14:1\/C6 ratio (reflecting the impaired action of the medium-chain acyl-Co A dehydrogenase), and the C4\/C6 ratio (reflecting the impaired action of short-chain acyl-Co A dehydrogenase) were significantly reduced immediately before eculizumab infusion, revealing impairments in the Acyl CoA metabolism, and reached levels similar to those in the healthy controls 24 hours after infusion.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>We demonstrated significant differences in the metabolomes of the PNH patients compared to healthy controls. Eculizumab infusion seemed to improve deficiencies in the acyl CoA metabolism and may have a role in the mitochondrial oxidative process of long and medium-chain fatty acids, reducing oxidative stress, and inflammation.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0289285","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T17:24:59Z","timestamp":1690910699000},"page":"e0289285","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Biochemical phenotyping of paroxysmal nocturnal hemoglobinuria reveals solute carriers and \u03b2-oxidation deficiencies"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5675-0893","authenticated-orcid":true,"given":"Patricia Eiko","family":"Yamakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Rita","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael Dale Cotrim","family":"Guerreiro da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matheus Vescovi","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirce Maria","family":"Marchioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Augusto Ferreira","family":"Carioca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Michonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celso","family":"Arrais-Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"key":"pone.0289285.ref001","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/0092-8674(93)90250-T","article-title":"Deficiency of the GPI Anchor Caused by a Somatic Mutation of the PIG-A Gene in Paroxysmal Nocturnal Hemoglobinuria","volume":"73","author":"J. Takeda","year":"1993","journal-title":"Cell"},{"key":"pone.0289285.ref002","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1172\/JCI114311","article-title":"Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria","volume":"84","author":"M. H. Holguin","year":"1989","journal-title":"J. Clin. Invest"},{"key":"pone.0289285.ref003","doi-asserted-by":"crossref","first-page":"17028","DOI":"10.1038\/nrdp.2017.28","article-title":"Paroxysmal nocturnal haemoglobinuria","volume":"3","author":"A. Hill","year":"2017","journal-title":"Nat. Rev. Dis. Prim"},{"key":"pone.0289285.ref004","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1182\/blood-2008-01-133918","article-title":"Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories","volume":"112","author":"RP de Latour","year":"2016","journal-title":"Blood"},{"key":"pone.0289285.ref005","first-page":"1","article-title":"Complement system part I\u2013molecular mechanisms of activation and regulation","volume":"6","author":"Nicolas S. Merle","year":"2015","journal-title":"Front. Immunol"},{"key":"pone.0289285.ref006","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0161-5890(96)00078-8","article-title":"Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv","volume":"33","author":"TC Thomas","year":"1996","journal-title":"Mol. Immunol"},{"key":"pone.0289285.ref007","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"P Hillmen","year":"2006","journal-title":"N. Engl. J. Med"},{"key":"pone.0289285.ref008","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1365-2141.2010.08096.x","article-title":"Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria","volume":"149","author":"A Hill","year":"2010","journal-title":"Br. J. Haematol"},{"key":"pone.0289285.ref009","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: Sustained efficacy and improved survival","volume":"117","author":"RJ Kelly","year":"2011","journal-title":"Blood"},{"key":"pone.0289285.ref010","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/2040620716681748","article-title":"Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician \u2018 s guide","volume":"8","author":"M. Griffin","year":"2017","journal-title":"Ther Adv Hematol"},{"key":"pone.0289285.ref011","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","article-title":"Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria","volume":"110","author":"P Hillmen","year":"2007","journal-title":"Blood"},{"issue":"10","key":"pone.0289285.ref012","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1182\/blood.2019003812","article-title":"How I treat paroxysmal nocturnal hemoglobinuria","volume":"137","author":"RA Brodsky","year":"2021","journal-title":"Blood"},{"key":"pone.0289285.ref013","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1182\/blood-2008-11-189944","article-title":"Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab","volume":"113","author":"AM Risitano","year":"2016","journal-title":"Blood"},{"key":"pone.0289285.ref014","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.copbio.2012.10.003","article-title":"Metabolomics platforms for genome wide association studies-linking the genome to the metabolome","volume":"24","author":"J. Adamski","year":"2013","journal-title":"Curr. Opin. Biotechnol"},{"key":"pone.0289285.ref015","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bbcan.2012.07.001","article-title":"A global view of the biochemical pathways involved in the regulation of the metabolism of cancer cells","volume":"1826","author":"P. Icard","year":"2012","journal-title":"Biochim. Biophys. Acta\u2014Rev. Cancer"},{"key":"pone.0289285.ref016","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1002\/pmic.201400255","article-title":"Basics of mass spectrometry based metabolomics","volume":"14","author":"F. Courant","year":"2014","journal-title":"Proteomics"},{"key":"pone.0289285.ref017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2010-07-299636","article-title":"Pathophysiology of sickle cell disease is mirrored by the red blood cell metabolome","volume":"117","author":"D Darghouth","year":"2011","journal-title":"Blood"},{"key":"pone.0289285.ref018","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI74604","article-title":"Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression","volume":"124","author":"Y Zhang","year":"2014","journal-title":"J. Clin. Invest"},{"key":"pone.0289285.ref019","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1182\/blood.V122.21.4675.4675","article-title":"Targeted Metabolomic Profiles Are Strongly Correlated With Metabolic Alterations In Patients With Sickle Cell\/Beta Thalassemia Disease","volume":"122","author":"I Papassotiriou","year":"2013","journal-title":"Blood"},{"key":"pone.0289285.ref020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep42249","article-title":"\u03b2-Thalassemia Patients Revealed a Significant Change of Untargeted Metabolites in Comparison to Healthy Individuals","volume":"7","author":"SG Musharraf","year":"2017","journal-title":"Sci. Rep"},{"key":"pone.0289285.ref021","doi-asserted-by":"crossref","first-page":"13709","DOI":"10.4238\/2015.October.28.33","article-title":"Abnormal metabolites related to bone marrow failure in aplastic anemia patients","volume":"14","author":"P. Zhong","year":"2015","journal-title":"Genet. Mol. Res"},{"key":"pone.0289285.ref022","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.thromres.2019.10.001","article-title":"First exploratory study on the metabolome from plasma exosomes in patients with paroxysmal nocturnal hemoglobinuria","volume":"183","author":"F Vallejo","year":"2019","journal-title":"Thromb Res"},{"key":"pone.0289285.ref023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2105-13-120","article-title":"On the hypothesis-free testing of metabolite ratios in genome-wide and metabolome-wide association studies","volume":"13","author":"AK Petersen","year":"2012","journal-title":"BMC Bioinformatics"},{"key":"pone.0289285.ref024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-8-102","article-title":"Newborn screening for medium-chain acyl-CoA dehydrogenase deficiency: Regional experience and high incidence of carnitine deficiency","volume":"8","author":"ML Couce","year":"2013","journal-title":"Orphanet J. Rare Dis"},{"key":"pone.0289285.ref025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000672","article-title":"Genetic determinants of circulating sphingolipid concentrations in European populations","volume":"5","author":"AA Hicks","year":"2009","journal-title":"PLoS Genet"},{"key":"pone.0289285.ref026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002490","article-title":"Genome-wide association study identifies novel loci associated with circulating phospho- and sphingolipid concentrations","volume":"8","author":"A Demirkan","year":"2012","journal-title":"PLoS Genet"},{"key":"pone.0289285.ref027","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1476-9255-9-37","article-title":"A new metabolomic assay to examine inflammation and redox pathways following LPS challenge","volume":"9","author":"J. H. Suh","year":"2012","journal-title":"J. Inflamm"},{"key":"pone.0289285.ref028","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.febslet.2005.02.050","article-title":"Thermolabile phenotype of carnitine palmitoyltransferase II variations as a predisposing factor for influenza-associated encephalopathy","volume":"579","author":"Y Chen","year":"2005","journal-title":"FEBS Lett"},{"key":"pone.0289285.ref029","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.chroma.2011.09.074","article-title":"Targeted metabolomic analysis of plasma samples for the diagnosis of inherited metabolic disorders","volume":"1226","author":"H Jane\u010dkov\u00e1","year":"2012","journal-title":"J. Chromatogr. A"},{"key":"pone.0289285.ref030","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/ng.507","article-title":"A genome wide perspective of genetic variation in human metabolism","volume":"42","author":"T Illig","year":"2010","journal-title":"Nat Genet"},{"key":"pone.0289285.ref031","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1007\/s11306-014-0641-2","article-title":"Basic amino acids and dimethylarginines targeted metabolomics discriminates primary hepatocarcinoma from hepatic colorectal metastases","volume":"10","author":"O. D\u2019Apolito","year":"2014","journal-title":"Metabolomics"},{"key":"pone.0289285.ref032","first-page":"432","article-title":"An Introduction to Pharmacotherapy for Inborn Errors of Metabolism","volume":"23","author":"A. A. Harthan","year":"2018","journal-title":"J. Pediatr. Pharmacol. Ther"},{"key":"pone.0289285.ref033","author":"WR Treem","year":"2011","journal-title":"Mitochondrial Hepatopathies in Pediatric Gastrointestinal and Liver Disease"},{"key":"pone.0289285.ref034","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/BF03261931","article-title":"Carnitine and acylcarnitines: Pharmacokinetic, pharmacological and clinical aspects","volume":"51","author":"S. E. Reuter","year":"2012","journal-title":"Clin. Pharmacokinet"},{"key":"pone.0289285.ref035","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/0005-2736(69)90055-8","article-title":"Lysis of erythrocytes by long-chain acyl esters of carnitine","volume":"193","author":"K. S. Cho","year":"1969","journal-title":"BBA\u2014Biomembr"},{"key":"pone.0289285.ref036","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.numecd.2017.07.011","article-title":"Inverse relations of serum phosphatidylcholines and lysophosphatidylcholines with vascular damage and heart rate in patients with atherosclerosis","volume":"28","author":"K Paapstel","year":"2018","journal-title":"Nutr. Metab. Cardiovasc. Dis"},{"issue":"1","key":"pone.0289285.ref037","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/bjh.18584","article-title":"Metabolomic profile in patients with primary warm autoimmune haemolytic anaemia","volume":"201","author":"IB Rabelo","year":"2023","journal-title":"Br J Haematol"},{"key":"pone.0289285.ref038","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jare.2018.04.002","article-title":"Impaired acylcarnitine profile in transfusion-dependent beta-thalassemia major patients in Bangladesh","volume":"12","author":"S Kumar Sarker","year":"2018","journal-title":"J. Adv. Res"},{"issue":"2","key":"pone.0289285.ref039","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1056\/NEJMra2201664","article-title":"Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibition","volume":"387","author":"R Notaro","year":"2022","journal-title":"N Engl J Med"},{"key":"pone.0289285.ref040","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: The 301 study","volume":"133","author":"JW Lee","year":"2019","journal-title":"Blood"},{"key":"pone.0289285.ref041","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0009-8981(70)90063-X","article-title":"Arginase activity in erythrocytes of healthy and ill children","volume":"28","author":"E Azizi","year":"1970","journal-title":"Clin. Chim. Acta"},{"key":"pone.0289285.ref042","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.hoc.2013.11.008","article-title":"Alterations of the arginine metabolome in sickle cell disease a growing rationale for arginine therapy","volume":"28","author":"C. R. Morris","year":"2014","journal-title":"Hematol. Oncol. Clin. North Am"},{"key":"pone.0289285.ref043","first-page":"167","article-title":"The role of the arginine metabolome in pain: Implications for sickle cell disease","volume":"9","author":"N. Bakshi","year":"2016","journal-title":"J. Pain Res"},{"key":"pone.0289285.ref044","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1253\/circj.CJ-11-0622","article-title":"Identification of biomarkers of stent restenosis with serum metabolomic profiling using gas chromatography\/mass spectrometry","volume":"76","author":"M Hasokawa","year":"2012","journal-title":"Circ. J"},{"key":"pone.0289285.ref045","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0306-3623(97)00309-1","article-title":"Review of some actions of taurine on ion channels of cardiac muscle cells and others","volume":"30","author":"H. Satoh","year":"1998","journal-title":"Gen. Pharmacol"},{"key":"pone.0289285.ref046","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jacc.2015.02.018","article-title":"Metabolic disturbances identified in plasma are associated with outcomes in patients with heart failure: Diagnostic and prognostic value of metabolomics","volume":"65","author":"ML Cheng","year":"2015","journal-title":"J. Am. Coll. Cardiol"},{"key":"pone.0289285.ref047","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/imj.13160","article-title":"Changing prognosis in Paroxysmal Nocturnal Haemoglobinuria disease subcategories; an analysis of International PNH Registry","volume":"46","author":"G Soci\u00e9","year":"2016","journal-title":"Intern med J"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0289285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T17:25:34Z","timestamp":1690910734000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0289285"}},"subtitle":[],"editor":[{"given":"Elsayed","family":"Abdelkreem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":47,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0289285","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}